

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: True Leaf Medicine International Ltd. (the "Issuer").

Trading Symbol: MJ

Number of Outstanding Listed Securities: 95,269,059 common shares (plus 11,447,382 common shares reserved for issuance in the form of 5,440,237 warrants and 6,007,145 options)

Date: March 5, 2018

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

During the past month, the Issuer generally continued to market its pet products and to develop its pet product line.

On February 14, 2018 the Issuer announced the launch of its Return the Love™ charitable giving program as a core part of its mission to be Canada's leading purpose-driven cannabis company.

With inaugural donations made to St. John Ambulance, Canada's leading first aid training and community service organization, and the BC Pets and Friends therapy dog programs, the Issuer is supporting the addition of volunteer therapy dog and handler teams to serve and benefit the wellbeing of seniors in care throughout the province. Moving forward, the Issuer plans to set aside a portion of its time and budget to support more charities as part of the Return the Love™ initiative.

The Issuer held its annual general and special meeting on February 27, 2018 where it re-elected directors Darcy Bomford, Michael Harcourt, Kevin Bottomley, and Christopher Spooner. The Issuer also re-appointed Davidson & Company LLP as its auditor for the fiscal year ending March 31, 2018. Special business at the meeting including approving amendments to the Issuer's Articles to change the shareholder meeting quorum requirements to "not less than 33 and 1/3 of the outstanding shares of the Issuer's voting shares" and to add provisions for the advance notice of director nominations. More information on these items may be found in the Issuer's Information Circular filed on SEDAR.

- 2. Provide a general overview and discussion of the activities of management.**

Please see Item 1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None, except in the ordinary course of business.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Issuer entered into an agreement with a branding and market positioning consultant to provide the Issuer with consulting services at a minimum cost of \$15,000 per month. The agreement has an initial one-year term ending February 15, 2019 with two one-year renewable terms, cancellable with 60-days notice by either party and payment of the prorated portion of the fees due. The consultant is not a related party.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None, except in the ordinary course of business.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None, except in the ordinary course of business.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Please see Item 1 above.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common Shares	397,921	These shares were issued on February 1, 2018 at various prices of \$0.15, \$0.185, and \$0.45 per share pursuant to warrant and option exercises.	\$75,538 for general working capital.
Common Shares	40,000	These shares were issued on February 7, 2018 at a price of \$0.45 per share pursuant to a warrant exercises.	\$18,000 for general working capital.
Options	2,000,000	2,000,000 stock options issued to directors, officers, and consultants to purchase up to a total of 2,000,000 common shares exercisable at a price of \$0.94 for a period of 5 years from February 6, 2018 being the date of grant. **100,000 of the stock option are exercisable	N/A

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
		only for 2 years from the date of grant.	
Common Shares	50,000	These shares were issued on February 14, 2018 at a price of \$0.185 per share pursuant to an option exercises.	\$9,250 for general working capital.
Common Shares	175,251	These shares were issued on February 16, 2018 at a price of \$0.12 per share pursuant to an option exercises.	\$21,030.12 for general working capital.
Common Shares	50,000	These shares were issued on February 19, 2018 at a price of \$0.395 per share pursuant to an option exercises.	\$19,750 for general working capital.

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None. _____

16. Provide details of any changes in directors, officers or committee members.

None. _____

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None. _____

[Certificate on Next Page]

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated March 5, 2018.

Darcy Bomford
Name of Director or Senior Officer

"Darcy Bomford"
Signature

Chief Executive Officer
Official Capacity

Issuer Details Name of Issuer	For Month End	Date of Report YY/MM/DD
True Leaf Medicine International Ltd.	February 2018	18/03/05
Issuer Address		
100 Kalamalka Lake Road, Unit 32		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vernon, British Columbia V1T 9G1	N/A	778.475.5323
Contact Name	Contact Position	Contact Telephone No.
Darcy Bomford	President, CEO, and Director	778.475.5323
Contact Email Address	Web Site Address	
Darcy@trueleaf.com	www.trueleaf.com	